Search research articles
Contact Us
Filters
Showing results (261-270 of 436) with videos related to
Page
of 44
Sort By:
Blood Cancer Journal
|
May 6, 2020
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype
Bachar Samra, Guillaume Richard-Carpentier, Tapan M Kadia, et al.
The Lancet. Haematology
|
December 4, 2018
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
Elias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
Cancer
|
April 7, 2025
Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial
Hannah Goulart, Hagop Kantarjian, Gautam Borthakur, et al.
Hemasphere
|
October 24, 2025
A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia
Wei-Ying Jen, Jennifer Croden, Emmanuel Almanza-Huante, et al.
American Journal of Hematology
|
September 4, 2020
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)
Koji Sasaki, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, et al.
Cancer
|
July 17, 2019
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia
Koji Sasaki, Hagop M Kantarjian, Tapan Kadia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 18, 2022
Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Naval Daver, Alexander E Perl, Joseph Maly, et al.
Leukemia
|
November 25, 2023
TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax
Anudishi Tyagi, Appalaraju Jaggupilli, Stanley Ly, et al.
The Lancet. Oncology
|
August 23, 2015
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
Jean-Pierre J Issa, Gail Roboz, David Rizzieri, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 10, 2023
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results
Koji Sasaki, Kiyomi Morita, Hagop Kantarjian, et al.
Page
of 44
Search research articles
Search
Showing results (261-270 of 436) with videos related to
Sort By:
Page
of 44
Blood Cancer Journal
|
May 6, 2020
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype
Bachar Samra, Guillaume Richard-Carpentier, Tapan M Kadia, et al.
The Lancet. Haematology
|
December 4, 2018
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
Elias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
Cancer
|
April 7, 2025
Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial
Hannah Goulart, Hagop Kantarjian, Gautam Borthakur, et al.
Hemasphere
|
October 24, 2025
A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia
Wei-Ying Jen, Jennifer Croden, Emmanuel Almanza-Huante, et al.
American Journal of Hematology
|
September 4, 2020
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)
Koji Sasaki, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, et al.
Cancer
|
July 17, 2019
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia
Koji Sasaki, Hagop M Kantarjian, Tapan Kadia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 18, 2022
Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Naval Daver, Alexander E Perl, Joseph Maly, et al.
Leukemia
|
November 25, 2023
TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax
Anudishi Tyagi, Appalaraju Jaggupilli, Stanley Ly, et al.
The Lancet. Oncology
|
August 23, 2015
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
Jean-Pierre J Issa, Gail Roboz, David Rizzieri, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 10, 2023
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results
Koji Sasaki, Kiyomi Morita, Hagop Kantarjian, et al.
Page
of 44